Table 2.

Pretransplant crossmatch results and time of diagnosis Single Antigen Bead assay results of acute allograft dysfunction patients and heart transplant recipient controls

Variable	AAD Patients (N=10)	Controls (N=30)	p-value
Pretransplant Crossmatch
Cytotoxic crossmatch positive	0	0	1.0
FLAP PRA positive (>10%)	0	0	1.0
FXM performed	6 (60%)	11 (37%)	0.02
T-cell FXM positive	1 (17%)	0
B-cell FXM positive	1 (17%)	0
Virtual crossmatch positive*	2 (20%)	2 (7%)	0.04
Anti-HLA class I DSA	1 (10%)	2 (7%)
Anti-HLA class II DSA	1 (10%)	0
Anti-HLA class I and II DSA	0	0
At AAD Diagnosis or Control Matching†
Positive DSA	4 (40%)	16 (53%)	0.43
Anti-HLA class I DSA	3 (30%)	2 (7%)	0.02
Mean peak class I (MFI)	1526 ± 2904	307 ± 1174	0.01
Mean cumulative class I (MFI)	3056 ± 6108	378 ± 1440	0.01
Anti-HLA class II DSA	3 (30%)	15 (50%)	0.05
Mean peak class II (MFI)	2229 ± 4538	1467 ± 3215	0.02
Mean cumulative class II (MFI)	6886 ± 17401	2476 ± 6434	<0.01
Anti-HLA class I and II DSA	2 (20%)	1 (3%)	0.03

^*Positive virtual crossmatch=MFI>2000.

^†Results compared at the time of diagnosis for AAD patients and at the time of matching for controls. Data are presented as mean ±standard deviation for continuous data or as frequency (percentage) for categorical data. AAD-acute allograft dysfunction, DSA-donor specific antibodies, FLAP=frozen lymphocyte antibody panel, FXM-flow cytometric crossmatch, HLA-human leukocyte antigen, MFI-mean fluorescence intensity, PRA-panel of reactive antibodies,